SG Americas Securities LLC Acquires Shares of 10,960 Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

SG Americas Securities LLC bought a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 10,960 shares of the company’s stock, valued at approximately $72,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LXEO. Values First Advisors Inc. bought a new position in shares of Lexeo Therapeutics during the third quarter valued at approximately $67,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Lexeo Therapeutics by 107.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock valued at $577,000 after acquiring an additional 33,013 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares in the last quarter. MetLife Investment Management LLC grew its stake in Lexeo Therapeutics by 121.5% in the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after purchasing an additional 7,803 shares during the period. Finally, Vestal Point Capital LP grew its stake in Lexeo Therapeutics by 1.2% in the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock worth $7,684,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on LXEO shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. HC Wainwright upped their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Leerink Partners reduced their price target on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 13th. Finally, Chardan Capital upped their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and an average target price of $23.80.

Lexeo Therapeutics Trading Up 6.8 %

NASDAQ LXEO opened at $4.22 on Friday. Lexeo Therapeutics, Inc. has a 12 month low of $3.84 and a 12 month high of $19.50. The stock has a market cap of $139.56 million, a P/E ratio of -1.34 and a beta of 2.99. The stock’s fifty day moving average price is $6.16 and its 200-day moving average price is $8.44. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.